Clinical trial
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory…
NCT00183924 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00183924 |
|---|---|
| Title | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. |
| Official title | A Phase II Pilot Study of Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Estramustine, Docetaxel, Carboplatin |
| Enrollment | 20 |
| Start date | Mar 1, 2001 |
| Primary completion | Jul 1, 2006 |
| Completion | Dec 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: